GlucoVista
Fairfield, US · Delaware corporation · 1 known investors
Medical device company developing the CGM-305, a wearable non-invasive continuous glucose monitor using thermal infrared sensing.
Also known as GlucoVista LLC
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.7M disclosed across 1 round · 2015
▶$2.7MraisedDec 2015 · 6 investors · Other Health CareRule 506(b)
- Efraim LandaExecutive Officer, Director
- Jonathan GerlitzDirector
- James BurkeDirector
- Anders BragDirector
- Offering amount
- $10M
- Amount sold
- $2.7M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026GlucoVista is a medical device company developing non-invasive, continuous glucose monitoring technology for people with Type 1 and Type 2 diabetes. Its lead product, the CGM-305, is described as a wearable, continuous non-invasive glucometer that determines blood glucose levels by capturing the natural thermal infrared radiation emitted at specific wavelengths by glucose in the blood. Because the measurement relies on passively detecting emitted radiation rather than sampling blood, the company characterizes the method as fully passive and truly non-invasive. The device is used together with a companion smartphone application.
The company has U.S. headquarters in Fairfield, New Jersey, at 277 Fairfield Rd., and also operates in Israel. It has several patents pending related to its glucose monitoring technology. As of December 2015 it was conducting clinical studies with hospitals in Israel.
Business model
GlucoVista develops a proprietary medical device, the CGM-305 wearable glucometer, paired with a companion mobile application, targeting patients who require ongoing glucose monitoring.
Traction
As of December 2015 the company had raised more than $2 million, reported $2.7 million from six investors in a Form D filing with the SEC, and was conducting clinical studies with hospitals in Israel.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
GlucoVista is one of a group of companies pursuing non-invasive glucose monitoring, an area often described as a long-standing goal in medical technology, particularly via spectroscopy. As of December 2015, none of the companies pursuing non-invasive approaches, including GlucoVista, had obtained 510(k) clearance from the U.S. Food and Drug Administration.
The CGM-305 measures glucose by detecting naturally emitted thermal infrared radiation rather than requiring blood sampling or an active illumination source, an approach the company describes as entirely passive. Competing non-invasive efforts cited in coverage, such as Integrity Applications' GlucoTrack and Socrates Health Solutions, use ear-clip based sensing.
Technology
The CGM-305 is a wearable continuous glucometer that reports blood glucose levels by capturing natural thermal infrared radiation emitted by glucose in the blood at specific wavelengths, a passive method requiring no blood sample. The system is paired with a companion app. The company holds several pending patents in non-invasive glucose measurement.
Go-to-market
Patients with Type 1 and Type 2 diabetes who need continuous glucose monitoring.
Geography
U.S. headquarters in Fairfield, New Jersey, with operations in Israel, where the company has conducted clinical studies with hospitals.
History
The company was co-founded by Efraim Landa, who also founded the venture firm Effi Enterprises and previously led Fidelity Medical, Inc. GlucoVista operates from Fairfield, New Jersey and Israel, and had accumulated several pending patents covering its non-invasive glucose monitoring approach. By late 2015 it had raised more than $2 million and was running clinical studies with hospitals in Israel. Its public website has since been placed in an under-construction state showing only company contact details.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsPress coverage reported that GlucoVista had raised more than $2 million to advance its non-invasive continuous glucose monitoring wearable, with $2.7 million raised from six investors per a Form D filing with the U.S. Securities and Exchange Commission.
$2.7M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 5
primary sources listed
- GlucoVistaglucovista.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does GlucoVista do?
- Medical device company developing the CGM-305, a wearable non-invasive continuous glucose monitor using thermal infrared sensing.
- Who are GlucoVista's investors?
- GlucoVista's investors include Ff Venture Capital.
- How much funding has GlucoVista raised?
- GlucoVista has disclosed $2.7M raised across 1 round.
- Where is GlucoVista headquartered?
- GlucoVista is headquartered in Fairfield, US.